Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database

被引:36
作者
Bhoi, Peter [1 ]
Bessette, Louis [2 ]
Bell, Mary J. [3 ]
Tkaczyk, Cathy [1 ]
Nantel, Francois [1 ]
Maslova, Karina [1 ]
机构
[1] Janssen Inc, Med Affairs, Toronto, ON, Canada
[2] Grp Rech Rhumatol & Malad Osseuses, Ste Foy, PQ, Canada
[3] Sunnybrook Hlth Sci Ctr, Dept Rheumatol, Toronto, ON, Canada
关键词
BLOCKER DOSE-ESCALATION; RHEUMATOID-ARTHRITIS; MEDICATION ADHERENCE; PHARMACY RECORDS; THERAPIES; FREQUENCY; IMPACT; MANAGEMENT; PREFERENCE; PATTERNS;
D O I
10.1136/bmjopen-2017-015872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Subcutaneous tumour necrosis factor alpha TNF alpha inhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable factor that may compromise patient outcomes. The aim of this analysis was to compare adherence and dosing interval of SC-TNFis in the treatment of people with inflammatory arthritis. Design We used the IMS Brogan database combining both Canadian private and public drug plan databases of Ontario and Quebec. Target drugs included SC-TNFis for inflammatory arthritis. The index period was from 1 January 2010 to 30 June 2012 and patients were followed for 24 months through 30 June 2014. Inclusion criteria were adult patients newly prescribed a SC-TNFis with at least three prescriptions and retained on therapy at 24 months. Dosing regimens as per the product monographs were used to compare actual versus expected drug utilisation. The mean possession ratio was used as a marker for adherence. Patients who scored > 80% were considered adherent. The average days between units was estimated by taking the total days on therapy and divided by the number of units the patient received. Results 4035 patients were included: 683 (16.9%), 1400 (34.7%), 1765 (43.7%) and 187 (4.6%) were treated with GLM, ADA, ETA and CZP, respectively. The proportion of adherent patients in the GLM cohort (n= 595/683, 87%, p< 0.0001) was greater compared with ADA (n= 1044/1400, 75%), ETA (n= 1285/1765, 73%) and CZP-treated patients (132/187, 71%). In addition, the number of patients receiving biological drug at a shorter dosing interval was similar between cohorts, and was 5%, 6%, 12% and 4% in GLM (<= 26 days), ADA (<= 12 days), ETA (<= 6 days) and CZP-treated patients (<= 12 days), respectively. Conclusions In this real-life administrative database, GLM had better adherence compared with other SC-TNFis.
引用
收藏
页数:6
相关论文
共 40 条
[1]  
[Anonymous], 2014, SIMPONI GOL PROD MON, P124
[2]  
[Anonymous], 2016, HUMIRA AD PROD MON, P141
[3]  
[Anonymous], 2014, CIMZIA CERT PEG PROD, P54
[4]  
[Anonymous], 2015, ENBREL ET PROD MON, P87
[5]   Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up [J].
Bartelds, Geertje M. ;
Krieckaert, Charlotte L. M. ;
Nurmohamed, Michael T. ;
van Schouwenburg, Pauline A. ;
Lems, Willem F. ;
Twisk, Jos W. R. ;
Dijkmans, A. C. ;
Aarden, Lucien ;
Wolbink, Gerrit Jan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (14) :1460-1468
[6]   MEDICATION ADHERENCE: HELPING PATIENTS TAKE THEIR MEDICINES AS DIRECTED [J].
Benjamin, Regina M. .
PUBLIC HEALTH REPORTS, 2012, 127 (01) :2-3
[7]   Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort [J].
Bluett, James ;
Morgan, Catharine ;
Thurston, Layla ;
Plant, Darren ;
Hyrich, Kimme L. ;
Morgan, Ann W. ;
Wilson, Anthony G. ;
Isaacs, John D. ;
Cordingley, Lis ;
Barton, Anne .
RHEUMATOLOGY, 2015, 54 (03) :494-499
[8]   Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting [J].
Blume, Steven W. ;
Fox, Kathleen M. ;
Joseph, George ;
Chuang, Chien-Chia ;
Thomas, Jessy ;
Gandra, Shravanthi R. .
ADVANCES IN THERAPY, 2013, 30 (05) :517-527
[9]  
Bonafede Machaon M K, 2012, J Med Econ, V15, P635, DOI 10.3111/13696998.2012.667028
[10]   Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs [J].
Borah, Bijan J. ;
Huang, Xingyue ;
Zarotsky, Victoria ;
Globe, Denise .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (06) :1365-1377